ArticleScientific reports2025
Cost effectiveness analysis of low dose computed tomography lung cancer screening in Chinese population.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study evaluated the economic benefits, optimal starting age, and most appropriate screening strategy for low-dose computed tomography (LDCT) lung cancer screening in the Chinese population from the perspective of the Chinese healthcare system. A Markov model was developed using previously published epidemiological and cost data from China to simulate the screening process for individuals aged 40 to 80. The analysis considered different starting ages (40, 45, 50, and 55 years) and screening intervals (annually, every two years, and every three years), resulting in 12 screening strategies and one no-screening strategy. The primary outcome was the incremental cost-effectiveness ratio (ICER). To validate the model, predicted lung cancer incidence rates were compared with actual incidence data from China, and the results showed consistency. The analysis identified age 55 as the optimal starting point for screening, with the strategy of screening every three years from age 55 to 80 emerging as the most cost-effective. Age 55 was thus determined to be the most appropriate starting age for initiating LDCT screening. This strategy yielded an ICER well below the per capita GDP of China in 2019, which was used as the willingness-to-pay (WTP) threshold in this study. One-way sensitivity analysis highlighted the cost of LDCT screening as the most influential parameter affecting the ICER. Probabilistic sensitivity analysis further confirmed the robustness of the findings: at a WTP threshold equal to the 2019 per capita GDP of China (71,453 CNY/QALY), the strategy of screening every three years from age 55 to 80 was cost-effective in nearly all simulations compared with no screening. In conclusion, when using the per capita GDP of China in 2019 as the WTP threshold, the optimal lung cancer screening strategy for the Chinese population was triennial LDCT screening from age 55 to 80. Sensitivity analyses consistently supported the robustness of this strategy's cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.